The National Health Control Agency (AnVisa) has announced a new procedure that requires preserving medical revenues to sell weight loss pens such as OZEPIC. The decision aims to improve control of access to these drugs, in response to an increase in negative events related to the use of the approved indicators.
Endocrine scientist Fabio Trujio, head of the Brazilian Association for obesity studies (ABSO), evaluates the measure as necessary. “the OzemPic“The semaglutido principle was clearly and randomly used,” says Trujillo.
Effects on the treatment of chronic diseases
Trujillo expresses its concern about how the new requirements affect the continuous treatment of patients with chronic diseases such as Diabetic And obesity. “My greatest interest is the patient’s arrival to the doctor to renew this renewal, and how it will be controlled,” it is backward.
The expert suggests that health of up to 90 days of revenue may be more appropriate, and avoid difficulties in reaching treatment. The AnVisa scale must become valid in mid -July, after 60 days of publication in the Federal Official Gazette.
Fighting to the parallel market
Anvisa’s decision also aims to combat the parallel market and irregular manipulation of these drugs. Trujillo warns of the risks associated with Double products“We see smuggling, and people who are besieged in angles with pens. When we talk about manipulation, it is important to think: What is the origin? Do we have real medications that show interest studies?”
The endocrine specialist emphasizes the importance of treating obesity as a chronic disease, and highlights the benefits of these medications not only for weight loss, but also to control diabetes, blood pressure and night breathing. He concludes that the battle is against Random use An illegal trade is very important to ensure the safety and effectiveness of treatment.
Ozepic and similar treatments help reduce the mental “food noise”
